Cargando…
Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview
Fibrosis is a common feature in most pathogenetic processes in the liver, and usually results from a chronic insult that depletes the regenerative capacity of hepatocytes and activates multiple inflammatory pathways, recruiting resident and circulating immune cells, endothelial cells, non-parenchyma...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912561/ https://www.ncbi.nlm.nih.gov/pubmed/31671842 http://dx.doi.org/10.3390/cells8111339 |
_version_ | 1783479485795926016 |
---|---|
author | Pinheiro, Daphne Dias, Isabelle Ribeiro Silva, Karina Stumbo, Ana Carolina Thole, Alessandra Cortez, Erika de Carvalho, Lais Weiskirchen, Ralf Carvalho, Simone |
author_facet | Pinheiro, Daphne Dias, Isabelle Ribeiro Silva, Karina Stumbo, Ana Carolina Thole, Alessandra Cortez, Erika de Carvalho, Lais Weiskirchen, Ralf Carvalho, Simone |
author_sort | Pinheiro, Daphne |
collection | PubMed |
description | Fibrosis is a common feature in most pathogenetic processes in the liver, and usually results from a chronic insult that depletes the regenerative capacity of hepatocytes and activates multiple inflammatory pathways, recruiting resident and circulating immune cells, endothelial cells, non-parenchymal hepatic stellate cells, and fibroblasts, which become activated and lead to excessive extracellular matrix accumulation. The ongoing development of liver fibrosis results in a clinically silent and progressive loss of hepatocyte function, demanding the constant need for liver transplantation in clinical practice, and motivating the search for other treatments as the chances of obtaining compatible viable livers become scarcer. Although initially cell therapy has emerged as a plausible alternative to organ transplantation, many factors still challenge the establishment of this technique as a main or even additional therapeutic tool. Herein, the authors discuss the most recent advances and point out the corners and some controversies over several protocols and models that have shown promising results as potential candidates for cell therapy for liver fibrosis, presenting the respective mechanisms proposed for liver regeneration in each case. |
format | Online Article Text |
id | pubmed-6912561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69125612020-01-02 Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview Pinheiro, Daphne Dias, Isabelle Ribeiro Silva, Karina Stumbo, Ana Carolina Thole, Alessandra Cortez, Erika de Carvalho, Lais Weiskirchen, Ralf Carvalho, Simone Cells Review Fibrosis is a common feature in most pathogenetic processes in the liver, and usually results from a chronic insult that depletes the regenerative capacity of hepatocytes and activates multiple inflammatory pathways, recruiting resident and circulating immune cells, endothelial cells, non-parenchymal hepatic stellate cells, and fibroblasts, which become activated and lead to excessive extracellular matrix accumulation. The ongoing development of liver fibrosis results in a clinically silent and progressive loss of hepatocyte function, demanding the constant need for liver transplantation in clinical practice, and motivating the search for other treatments as the chances of obtaining compatible viable livers become scarcer. Although initially cell therapy has emerged as a plausible alternative to organ transplantation, many factors still challenge the establishment of this technique as a main or even additional therapeutic tool. Herein, the authors discuss the most recent advances and point out the corners and some controversies over several protocols and models that have shown promising results as potential candidates for cell therapy for liver fibrosis, presenting the respective mechanisms proposed for liver regeneration in each case. MDPI 2019-10-29 /pmc/articles/PMC6912561/ /pubmed/31671842 http://dx.doi.org/10.3390/cells8111339 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pinheiro, Daphne Dias, Isabelle Ribeiro Silva, Karina Stumbo, Ana Carolina Thole, Alessandra Cortez, Erika de Carvalho, Lais Weiskirchen, Ralf Carvalho, Simone Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview |
title | Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview |
title_full | Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview |
title_fullStr | Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview |
title_full_unstemmed | Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview |
title_short | Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview |
title_sort | mechanisms underlying cell therapy in liver fibrosis: an overview |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912561/ https://www.ncbi.nlm.nih.gov/pubmed/31671842 http://dx.doi.org/10.3390/cells8111339 |
work_keys_str_mv | AT pinheirodaphne mechanismsunderlyingcelltherapyinliverfibrosisanoverview AT diasisabelle mechanismsunderlyingcelltherapyinliverfibrosisanoverview AT ribeirosilvakarina mechanismsunderlyingcelltherapyinliverfibrosisanoverview AT stumboanacarolina mechanismsunderlyingcelltherapyinliverfibrosisanoverview AT tholealessandra mechanismsunderlyingcelltherapyinliverfibrosisanoverview AT cortezerika mechanismsunderlyingcelltherapyinliverfibrosisanoverview AT decarvalholais mechanismsunderlyingcelltherapyinliverfibrosisanoverview AT weiskirchenralf mechanismsunderlyingcelltherapyinliverfibrosisanoverview AT carvalhosimone mechanismsunderlyingcelltherapyinliverfibrosisanoverview |